niacinamide has been researched along with Leukemia, Megakaryoblastic, Acute in 1 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
Leukemia, Megakaryoblastic, Acute: An acute myeloid leukemia in which 20-30% of the bone marrow or peripheral blood cells are of megakaryocyte lineage. MYELOFIBROSIS or increased bone marrow RETICULIN is common.
| Excerpt | Relevance | Reference |
|---|---|---|
| " A novel nicotinamide, AMG 706, was identified as a potent, orally bioavailable inhibitor of the VEGFR1/Flt1, VEGFR2/kinase domain receptor/Flk-1, VEGFR3/Flt4, platelet-derived growth factor receptor, and Kit receptors in preclinical models." | 1.33 | AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. ( Alva, G; Bready, J; Cattley, R; Chen, D; Coxon, A; DeMelfi, T; Diaz, Z; Estrada, J; Gan, Y; Kaufman, S; Kendall, R; Kumar, G; Meyer, J; Montestruque, S; Neervannan, S; Patel, V; Polverino, A; Radinsky, R; Starnes, C; Talvenheimo, J; Tasker, A; Wang, L, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Polverino, A | 1 |
| Coxon, A | 1 |
| Starnes, C | 1 |
| Diaz, Z | 1 |
| DeMelfi, T | 1 |
| Wang, L | 1 |
| Bready, J | 1 |
| Estrada, J | 1 |
| Cattley, R | 1 |
| Kaufman, S | 1 |
| Chen, D | 1 |
| Gan, Y | 1 |
| Kumar, G | 1 |
| Meyer, J | 1 |
| Neervannan, S | 1 |
| Alva, G | 1 |
| Talvenheimo, J | 1 |
| Montestruque, S | 1 |
| Tasker, A | 1 |
| Patel, V | 1 |
| Radinsky, R | 1 |
| Kendall, R | 1 |
1 other study available for niacinamide and Leukemia, Megakaryoblastic, Acute
| Article | Year |
|---|---|
AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Endothelium | 2006 |